ClinicalTrials.gg
TerminatedNCT02322814Updated Apr 13, 2023Results posted

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

A Phase 2 interventional study of Cobimetinib and Paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 53 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
87th of 361
169 · median 60
Started
2015
with 7 others
Phase 2
205 of 373
20 open now
Registered
266th of 373
by date
Lead sponsor
9 of 373
Hoffmann-La Roche

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 87th largest by enrollment of the 361 interventional ones that give a count, is one of 8 that started in 2015, is one of 205 in phase 2, and was the 266th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for metastatic breast cancer (MBC). Participants may continue on study treatment until the development of progressive disease (PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The Cohort I target sample size is 12 participants for the safety run-in stage and approximately 90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety run-in stage of approximately 15 participants followed by an expansion stage of approximately 15 participants.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 or 1
  • confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 ()-negative adenocarcinoma of the breast with measurable or locally advanced disease
  • Locally advanced disease must not be amenable to resection with curative intent
  • , according to , v1.1
  • Adequate hematologic and end organ function
  • Agreement to use highly effective methods as stated in protocol

Exclusion criteria

Exclusion Criteria:

Disease-Specific Exclusion Criteria

  • Known -, ER-positive, or PR-positive breast cancer by local laboratory assessment
  • Any prior chemotherapy, hormonal, or targeted therapy, for inoperable locally advanced or triple-negative breast cancer (mTNBC)
  • Any systemic anticancer therapy within 3 weeks prior to Cycle 1, Day 1
  • Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1
  • Major surgical procedure, open , or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during the course of the study
  • Prior exposure to experimental treatment targeting rapidly accelerated fibrosarcoma (Raf), MAP kinase/ERK kinase (MEK), or the mitogen-activated protein kinase (MAPK) pathway
  • (symptomatic or nonsymptomatic) that have not been treated previously, are progressive, or require any type of therapy (e.g., radiation, surgery, or ) to control symptoms from brain metastases within 30 days prior to first study treatment dose

Cobimetinib-Specific Exclusion Criteria

  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
  • Cobimetinib is metabolized by the hepatic cytochrome P3A4 () enzyme. Drugs CYP3A4/5 inhibitors and inducers should be avoided

Atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only)

  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of disease
  • Prior allogenic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive test for (HIV)
  • Active (defined as having a positive hepatitis B surface antigen [HBsAg] or positive hepatitis B virus [HBV] deoxyribonucleic acid [DNA] test at screening) or
  • Active tuberculosis
  • Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
  • Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (), anti-programmed death-1 (anti-PD-1), or anti-programmed death ligand-1 (anti-PD-L1) therapeutic antibodies
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or Interlukin-2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
  • Treatment with systemic corticosteroids or other systemic medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial

Cardiac Exclusion Criteria

  • History of cardiac dysfunction
  • interval at screening greater than (>) 480 milliseconds (ms) (average of triplicate screening measurements)
  • (LVEF) below the institutional lower limit of normal or below 50 percent (%), whichever is lower

General Exclusion Criteria

  • No other history of or ongoing that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assay
  • Pregnancy (positive serum pregnancy test) or lactation
  • Uncontrolled serious medical or psychiatric illness
  • Active infection requiring IV antibiotics on Cycle 1, Day 1
  • Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    Cohort I: Cobimetinib, Paclitaxel

    Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.

    Drug: Cobimetinib · Drug: Paclitaxel

  • Placebo comparator
    Cohort I: Placebo, Paclitaxel

    Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.

    Drug: Paclitaxel · Drug: Placebo

  • Experimental
    Cohort II:Cobimetinib,Paclitaxel,Atezolizumab

    Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.

    Drug: Cobimetinib · Drug: Paclitaxel · Drug: Atezolizumab

  • Experimental
    Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab

    Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.

    Drug: Cobimetinib · Drug: Atezolizumab · Drug: Nab-Paclitaxel

Interventions

  • Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.

    Also known as: GDC-0973; RO5514041; XL518

  • Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.

  • DrugPlacebo

    Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.

  • Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.

    Also known as: MPDL3280A

  • Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.

06

What researchers measure

Primary outcomes

  1. Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)

  2. Cohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1

    OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

    Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 5.25 years)

Secondary outcomes

  1. Cohort I, II, III: Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause

    Time frame: Randomization up to death from any cause (up to approximately 6.5 years)

  2. Cohort I: Percentage of Participants With Confirmed OR (PR or CR), as Determined by the Investigator Using RECIST v1.1

    OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

    Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)

  3. Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1

    DOR was defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator using RECIST v1.1 or death from any cause during the study, whichever occurred first.

    Time frame: Time from the first occurrence of documented objective response to time of relapse or death, whichever occurs first (up to approximately 6.5 years)

  4. Cohort I, II, III: Percentage of Participants With Unconfirmed Overall Response (OR_uc) (Unconfirmed PR or CR), as Determined by the Investigator Using RECIST v1.1

    ORR_uc (ORR confirmation not required) was defined as the rate of a PR or CR occurring after randomization as determined by the investigator using RECIST v1.1, confirmation not required. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

    Time frame: Randomization up to disease progression or relapse, whichever occurs fist (up to approximately 6.5 years)

  5. Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1

    PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

    Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 6.5 years)

  6. Cohort I, II, III: Percentage of Participants With Adverse Events (AEs)

    Time frame: Randomization up to end of study (up to approximately 6.5 years)

  7. Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib

    Time frame: Safety Run-In: Predose (Hour [Hr] 0) on Cycle (Cy) 1 Day (D) 8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)

  8. Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib

    Time frame: Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)

  9. Cohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib

    Time frame: Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15 (Cy=28 days)

  10. Cohort I, II: Cmax of Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)

  11. Cohort I, II: Cmin of Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)

  12. Cohort I: AUC0-tau of Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)

  13. Cohort III: Cmax of Nab-Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)

  14. Cohort III: Cmin of Nab-Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)

  15. Cohort III: AUC0-tau of Nab-Paclitaxel

    Time frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)

  16. Cohort II, III: Cmax (in Serum) of Atezolizumab

    Time frame: Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to end of treatment (EOT); 120 days after EOT (approximately 5.25 years) (Cy=28 days)

  17. Cohort II, III: Cmin (in Serum) of Atezolizumab

    Time frame: Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT; 120 days after EOT (approximately 5.5 years) (Cy=28 days)

  18. Cohort II, III: AUC0-tau (in Serum) of Atezolizumab

    Time frame: Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT (approximately 5.5 years); 120 days after EOT (approximately 5.5 years) (Cy=28 days)

07

Results

Posted Nov 13, 2019

Participant flow

The study recruited participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who had not received prior systemic therapy for metastatic breast cancer. Locally advanced disease must not have been amenable to resection with curative intent.

Participant flow — Overall Study
MilestoneCohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Started1643473231
Completed00000
Not completed1643473231
Withdrew: Death729322314
Withdrew: Lost to follow-up13310
Withdrew: Various reasons20110
Withdrew: Progressive disease00011
Withdrew: Protocol violation10000
Withdrew: Study terminated by sponsor079513
Withdrew: Withdrawal by subject54213

Outcome measures

PrimaryCohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)
Reported as:
Median · Weeks
Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
WeeksCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, Paclitaxel
Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)23.71 (18.14 to 32.14)16.43 (8.14 to 31.14)
Statistical analysis
  • Cohort I: Cobimetinib, Paclitaxel vs Cohort I: Placebo, Paclitaxel · Log Rank · p = 0.2470 · Hazard ratio (hr): 0.73 · 95% CI 0.43 to 1.24
PrimaryCohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1

OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

Time frame:
Randomization up to disease progression or relapse, whichever occurs first (up to approximately 5.25 years)
Reported as:
Number · Percentage of participants
Cohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1
Percentage of participantsCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Responders37.532.3
Non-Responders62.567.7
SecondaryCohort I, II, III: Overall Survival (OS)

OS was defined as the time from randomization to death from any cause

Time frame:
Randomization up to death from any cause (up to approximately 6.5 years)
Reported as:
Median · Months
Cohort I, II, III: Overall Survival (OS)
MonthsCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort I, II, III: Overall Survival (OS)16.72 (13.50 to 20.24)19.58 (14.75 to 29.37)11.04 (9.53 to 22.51)15.57 (14.26 to NA)
Statistical analysis
  • Cohort I: Cobimetinib, Paclitaxel vs Cohort I: Placebo, Paclitaxel · Log Rank · p = 0.5912 · Hazard ratio (hr): 1.18 · 95% CI 0.65 to 2.13
SecondaryCohort I: Percentage of Participants With Confirmed OR (PR or CR), as Determined by the Investigator Using RECIST v1.1

OR was defined as the rate of a PR or CR occurring after randomization and confirmed \>=28 days later as determined by the investigator using RECIST v1.1. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

Time frame:
Randomization up to disease progression or relapse, whichever occurs first (up to approximately 2 years)
Reported as:
Number · Percentage of participants
Cohort I: Percentage of Participants With Confirmed OR (PR or CR), as Determined by the Investigator Using RECIST v1.1
Percentage of participantsCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, Paclitaxel
Responders38.320.9
Non-responders61.779.1
SecondaryCohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1

DOR was defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator using RECIST v1.1 or death from any cause during the study, whichever occurred first.

Time frame:
Time from the first occurrence of documented objective response to time of relapse or death, whichever occurs first (up to approximately 6.5 years)
Reported as:
Median · Months
Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1
MonthsCohort I: Safety Run-InCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.139.29 (23.14 to 56.29)23.14 (16.14 to 26.57)24.14 (17.14 to NA)5.78 (4.44 to 16.33)11.42 (5.78 to 17.94)
SecondaryCohort I, II, III: Percentage of Participants With Unconfirmed Overall Response (OR_uc) (Unconfirmed PR or CR), as Determined by the Investigator Using RECIST v1.1

ORR_uc (ORR confirmation not required) was defined as the rate of a PR or CR occurring after randomization as determined by the investigator using RECIST v1.1, confirmation not required. As per RECIST v1.1, CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target and new measurable lesions.

Time frame:
Randomization up to disease progression or relapse, whichever occurs fist (up to approximately 6.5 years)
Reported as:
Number · Percentage of participants
Cohort I, II, III: Percentage of Participants With Unconfirmed Overall Response (OR_uc) (Unconfirmed PR or CR), as Determined by the Investigator Using RECIST v1.1
Percentage of participantsCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Responders42.625.646.945.2
Non-Responders57.474.453.154.8
SecondaryCohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1

PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1. As per RECIST v1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Time frame:
Randomization up to disease progression or relapse, whichever occurs first (up to approximately 6.5 years)
Reported as:
Median · Months
Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1
MonthsCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.13.75 (3.02 to 7.29)7.66 (3.65 to 11.04)
SecondaryCohort I, II, III: Percentage of Participants With Adverse Events (AEs)
Time frame:
Randomization up to end of study (up to approximately 6.5 years)
Reported as:
Count of participants · Participants
Cohort I, II, III: Percentage of Participants With Adverse Events (AEs)
ParticipantsCohort I: Safety Run-InCohort I: Cobimetinib, PaclitaxelCohort I: Placebo, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort I, II, III: Percentage of Participants With Adverse Events (AEs)1546433230
SecondaryCohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib
Time frame:
Safety Run-In: Predose (Hour [Hr] 0) on Cycle (Cy) 1 Day (D) 8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)
Reported as:
Geometric mean · Nanograms per millilitre (ng/mL)
Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib
Nanograms per millilitre (ng/mL)Cohort I: Safety Run-InCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib285 ± 62.2266 ± 82.0213 ± 68.0407 ± 90.7
SecondaryCohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib
Time frame:
Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose (2, 4 Hr postdose for Cohorts II, III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib
ng/mLCohort I: Safety Run-InCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib65.6 ± 1279.5130 ± 190.7138 ± 79.0136 ± 67.2
SecondaryCohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib
Time frame:
Safety Run-In: Predose (Hr 0) on Cy 1 D8; predose (Hr 0), 0.5, 1, 2, 4, 6 Hr postdose on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · Nanograms/milliliter/hour (hr*ng/mL)
Cohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib
Nanograms/milliliter/hour (hr*ng/mL)Cohort I: Safety Run-In
Cohort I: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib1620 ± 80.0
SecondaryCohort I, II: Cmax of Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort I, II: Cmax of Paclitaxel
ng/mLCohort I: Safety Run-InCohort II:Cobimetinib,Paclitaxel,Atezolizumab
Cohort I, II: Cmax of Paclitaxel1770 ± 553.4283 ± 490.9
SecondaryCohort I, II: Cmin of Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort I, II: Cmin of Paclitaxel
ng/mLCohort I: Safety Run-InCohort II:Cobimetinib,Paclitaxel,Atezolizumab
Cohort I, II: Cmin of Paclitaxel1.40 ± 89.91.26 ± 53.3
SecondaryCohort I: AUC0-tau of Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (infusion duration: 1 Hr) on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · hr*ng/mL
Cohort I: AUC0-tau of Paclitaxel
hr*ng/mLCohort I: Safety Run-In
Cohort I: AUC0-tau of Paclitaxel4220 ± 310.4
SecondaryCohort III: Cmax of Nab-Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort III: Cmax of Nab-Paclitaxel
ng/mLCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort III: Cmax of Nab-Paclitaxel277 ± 658.5
SecondaryCohort III: Cmin of Nab-Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort III: Cmin of Nab-Paclitaxel
ng/mLCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort III: Cmin of Nab-Paclitaxel2.05 ± 173.9
SecondaryCohort III: AUC0-tau of Nab-Paclitaxel
Time frame:
Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28 days)

No measurements were reported for this outcome.

SecondaryCohort II, III: Cmax (in Serum) of Atezolizumab
Time frame:
Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to end of treatment (EOT); 120 days after EOT (approximately 5.25 years) (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort II, III: Cmax (in Serum) of Atezolizumab
ng/mLCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort II, III: Cmax (in Serum) of Atezolizumab346 ± 48.3374 ± 38.8
SecondaryCohort II, III: Cmin (in Serum) of Atezolizumab
Time frame:
Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT; 120 days after EOT (approximately 5.5 years) (Cy=28 days)
Reported as:
Geometric mean · ng/mL
Cohort II, III: Cmin (in Serum) of Atezolizumab
ng/mLCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Cohort II, III: Cmin (in Serum) of Atezolizumab144 ± 34.6109 ± 89.9
SecondaryCohort II, III: AUC0-tau (in Serum) of Atezolizumab
Time frame:
Safety Run-In, Expansion: Predose (Hr 0), 0.5 Hr postdose (infusion duration: 1 Hr) on D1 of Cy1, 3; predose (Hr 0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT (approximately 5.5 years); 120 days after EOT (approximately 5.5 years) (Cy=28 days)

No measurements were reported for this outcome.

Adverse events

Collected over From randomization up until 6.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I: Safety Run-In7/16 (43.8%)6/16 (37.5%)15/16 (93.8%)
Cohort I: Placebo, Paclitaxel29/43 (67.4%)8/43 (18.6%)43/43 (100%)
Cohort I: Cobimetinib, Paclitaxel32/47 (68.1%)17/47 (36.2%)46/47 (97.9%)
Cohort II:Cobimetinib,Paclitaxel,Atezolizumab23/32 (71.9%)16/32 (50%)32/32 (100%)
Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab14/31 (45.2%)15/30 (50%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventCohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
PYREXIAGeneral disorders2/160/436/474/322/30
CELLULITISInfections and infestations0/160/434/471/320/30
DIARRHOEAGastrointestinal disorders0/160/431/472/322/30
MASTITISInfections and infestations0/160/430/471/322/30
URINARY TRACT INFECTIONInfections and infestations0/161/433/470/322/30
MITRAL VALVE INCOMPETENCECardiac disorders1/160/430/470/320/30
ASTHENIAGeneral disorders1/161/430/470/320/30
MUCOSAL INFLAMMATIONGeneral disorders0/160/430/472/320/30
ERYSIPELASInfections and infestations1/160/431/470/320/30
BRAIN OEDEMANervous system disorders1/160/430/470/320/30
Most frequent other events
Showing 10 of 158
Most frequent other events
EventCohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
DIARRHOEAGastrointestinal disorders10/1613/4336/4721/3227/30
RASHSkin and subcutaneous tissue disorders8/165/4322/4712/3217/30
NAUSEAGastrointestinal disorders7/1618/4320/4713/3215/30
ALOPECIASkin and subcutaneous tissue disorders5/1619/4321/478/3210/30
ANAEMIABlood and lymphatic system disorders3/166/4312/4714/3210/30
VOMITINGGastrointestinal disorders5/167/438/479/3212/30
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations6/160/4310/475/327/30
FATIGUEGeneral disorders3/1615/4313/4711/3210/30
STOMATITISGastrointestinal disorders5/165/4313/475/325/30
NEUTROPENIABlood and lymphatic system disorders2/1613/438/476/328/30

Baseline characteristics

The intent-to-treat (ITT) population was defined as all enrolled participants, whether or not the assigned study treatment was received.

Age, Continuous
Age, Continuous(Years)Cohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, AtezolizumabTotal
Mean53.6 ± 12.752.9 ± 13.754.2 ± 10.353.7 ± 13.152.2 ± 11.853.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, AtezolizumabTotal
Female1643473231169
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, AtezolizumabTotal
Hispanic or Latino1732316
Not Hispanic or Latino1335413028147
Unknown or Not Reported213006
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort I: Safety Run-InCohort I: Placebo, PaclitaxelCohort I: Cobimetinib, PaclitaxelCohort II:Cobimetinib,Paclitaxel,AtezolizumabCohort III: Cobimetinib, Nab-Paclitaxel, AtezolizumabTotal
American Indian or Alaska Native000000
Asian39112530
Native Hawaiian or Other Pacific Islander000000
Black or African American202105
White1034322825129
More than one race000000
Unknown or Not Reported102115
08

Study locations

53 sites
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256-6932, United States
  • Mercy Hospital, a Campus of Plantation General Hospital
    Miami, Florida 33133, United States
  • Florida Hospital Cancer Inst
    Orlando, Florida 32804, United States
  • Florida Cancer Research Institute
    Plantation, Florida 33324, United States
  • Cancer Treatment Centers of America
    Newnan, Georgia 30265, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Montefiore Einstein Cancer Center
    Bronx, New York 10461, United States
  • Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Peter MacCallum Cancer Centre; Medical Oncology
    Melbourne, Victoria 3000, Australia
  • St John of God Murdoch Hospital; Oncology West
    Murdoch, Western Australia 6150, Australia
  • Clinique Edith Cavell
    Bruxelles, 1180, Belgium
  • AZ Sint Lucas (Sint Lucas)
    Gent, 9000, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • AZ Sint Augustinus Veurne
    Veurne, 8630, Belgium
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Multiscan s.r.o.
    Pardubice, 532 03, Czechia
  • Centre Oscar Lambret
    Lille, 59020, France
  • Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
    Montpellier, 34298, France
  • Hopital Tenon
    Paris, 75020, France
  • Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer
    Rennes, 35000, France
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Azienda Ospedaliero Universitaria Seconda Università Degli Studi Di Napoli
    Napoli, Campania 80131, Italy
  • A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2
    Bologna, Emilia-Romagna 40138, Italy
  • Centro Di Riferimento Oncologico; SOC Oncologia Medica C
    Aviano, Friuli-Venezia Giulia 33081, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Lazio 00168, Italy
  • Istituto Europeo Di Oncologia
    Milano, Lombardia 20141, Italy
  • Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico
    Pisa, Toscana 56126, Italy
  • National Cancer Center; Medical Oncology
    Gyeonggi-do, 410-769, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
  • Yonsei University Health System/Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Pauls Stradins Clinical University Hospital
    R?ga, LV-1002, Latvia
  • Riga East Clinical University Hospital Latvian Oncology Centre
    Riga, LV-1079, Latvia
  • Prof. Dr. I. Chiricuta Institute of Oncology
    Cluj Napoca, 400015, Romania
  • Oncology Center Sf. Nectarie
    Craiova, 200347, Romania
  • Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
    Sabadell, Barcelona 8208, Spain
  • Organización Sanitaria Integrada Bilbao Basurto
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitario Infanta Cristina; Servicio de Oncologia
    Badajoz, 06080, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Fundacion Jimenez Diaz; Servicio de Oncologia
    Madrid, 28040, Spain
  • Hospital Clinico San Carlos; Servicio de Nefrologia
    Madrid, 28040, Spain
  • Hosp. Regional Univ. de Malaga ? Hospital Materno Infantil; Hospital Materno Infantil de Malaga
    Malaga, 29011, Spain
  • Chang Gung Memorial Hospital
    Kaohsiung Country, 833, Taiwan
  • Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
    Taipei City, 11259, Taiwan
  • Nuffield Health Bournemouth Hospital
    Bournemouth, BH1 1RW, United Kingdom
  • Mount Vernon Hospital
    Middlesex, HA6 2RN, United Kingdom
  • Nottingham University Hospitals City Campus
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Barteselli G, Goodman GR, Patel Y, Caro I, Xue C, McCallum S. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf. 2022 Dec;45(12):1491-1499. doi: 10.1007/s40264-022-01248-2. Epub 2022 Oct 30. PubMed 36310331 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Aug 2018, 40 months.

Results were first posted in Nov 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2014
First posted
Dec 23, 2014
StartActual
Mar 12, 2015
Primary completionActual
Aug 10, 2018
CompletionActual
Sep 17, 2021
Results first posted
Nov 13, 2019
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02322814
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 23, 2014
Start date
Mar 12, 2015
Primary completion
Aug 10, 2018
Completion
Sep 17, 2021
Results posted
Nov 13, 2019
Last update
Apr 13, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobimetinib · Paclitaxel · Atezolizumab

Start the discussion